Your browser doesn't support javascript.
loading
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Maraka, Stefania; Groves, Morris D; Mammoser, Aaron G; Melguizo-Gavilanes, Isaac; Conrad, Charles A; Tremont-Lukats, Ivo W; Loghin, Monica E; O'Brien, Barbara J; Puduvalli, Vinay K; Sulman, Erik P; Hess, Kenneth R; Aldape, Kenneth D; Gilbert, Mark R; de Groot, John F; Alfred Yung, W K; Penas-Prado, Marta.
Affiliation
  • Maraka S; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Groves MD; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mammoser AG; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Melguizo-Gavilanes I; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Conrad CA; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tremont-Lukats IW; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Loghin ME; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • O'Brien BJ; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Puduvalli VK; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sulman EP; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hess KR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Aldape KD; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gilbert MR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • de Groot JF; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alfred Yung WK; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Penas-Prado M; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 125(3): 424-433, 2019 02 01.
Article in En | MEDLINE | ID: mdl-30359477
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Brain Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Memantine / Mefloquine / Glioblastoma / Temozolomide / Metformin Type of study: Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Brain Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Memantine / Mefloquine / Glioblastoma / Temozolomide / Metformin Type of study: Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article